ME00152B - Nove farmaceutske kompozicije 4-(4-(3-(4-hlor0 -3-trifluorometil-fenil)-ureid0)-3-fluoro-fenoksi)piridin-2-karbonska kiseline za lečenje hiper-prolifera tivnih poremećaja - Google Patents
Nove farmaceutske kompozicije 4-(4-(3-(4-hlor0 -3-trifluorometil-fenil)-ureid0)-3-fluoro-fenoksi)piridin-2-karbonska kiseline za lečenje hiper-prolifera tivnih poremećajaInfo
- Publication number
- ME00152B ME00152B MEP-2008-358A MEP2008358A ME00152B ME 00152 B ME00152 B ME 00152B ME P2008358 A MEP2008358 A ME P2008358A ME 00152 B ME00152 B ME 00152B
- Authority
- ME
- Montenegro
- Prior art keywords
- composition according
- solid dispersion
- compound
- formula
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 13
- 238000011282 treatment Methods 0.000 title claims abstract 4
- 230000003463 hyperproliferative effect Effects 0.000 title claims abstract 3
- BZESFMLUNMTDFR-UHFFFAOYSA-N 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]pyridine-2-carboxylic acid Chemical compound C1=NC(C(=O)O)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 BZESFMLUNMTDFR-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 16
- 239000007962 solid dispersion Substances 0.000 claims abstract 14
- 150000001875 compounds Chemical class 0.000 claims abstract 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract 5
- 201000011510 cancer Diseases 0.000 claims abstract 5
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 25
- 239000011159 matrix material Substances 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 7
- 239000011230 binding agent Substances 0.000 claims 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 238000001125 extrusion Methods 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims 2
- 239000008109 sodium starch glycolate Substances 0.000 claims 2
- 238000000935 solvent evaporation Methods 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 108091008611 Protein Kinase B Proteins 0.000 claims 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101150001535 SRC gene Proteins 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 239000005441 aurora Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229920001531 copovidone Polymers 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims 1
- 238000005096 rolling process Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000009331 sowing Methods 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Abstract
Ovaj pronalazak se odnosi na nove farmaceutske kompozicije koje se sastoje od čvrste disperzije jedinjenja Formule (I), napostupke za pripremanje ovih novih farmaceutskih kompozicija i na njihovu upotrebu za lečenje hiper-proliferativnih poremećaja, kao što je kancer, bilo kao samostalno sredstvo ili u kombinaciji sa drugim terapijama.
Claims (35)
1.Kompozicija, naznačena time , što sadrži 4{4-[3-(4-hloro-3- trifluorometilfenil) -ureido]-3-fluorofenoksi}-piridin-2-karbonska kiselina metil amid i/ili njegove soli, hidrate. solvate u obliku čvrste disperzije.
2.Kompozicija, naznačena time , što se sastoji od čvrste suspenzije koja sadrži bar jedno jedinjenje Formule l i farmaceutski prihvatljivu matricu.
3.Kompozicija prema zahtevu 2, naznačena time , što se matrica sastoji od polimernih vezivnih sredstava ili ne-polimernih vezivnih sredstava koja su sposobna da rastvore ili disperguju jedinjenje Formule l.
4.Kompozicija prema zahtevu 2, naznačena time, što se matrica sastoji od kombinacije polimernih vezivnih sredstava i ne-polimernih vezivnih sredstava koja su sposobna da rastvore ili disperguju jedinjenje Formule l.
5.Kompozicija prema zahtevu 2, naznačena time , što se matrica sastoji od u vodi rastvorljivog polimera.
6.Kompozicija prema zahtevu 5, naznačena time, što se matrica sastoji od bar jednog polimera iz grupe koja sadrži polivinilpirolidon, copovidon, hidroksipropil celulozu, hidroksipropil metil celulozu, polietilen glikol ili polietilen oksid.
7.Kompozicija prema zahtevu 6, naznačena time, što se upotrebljava polivinilpirolidon kao sredstvo matrice.
8.Kompozicija prema zahtevu 7, naznačena time, što je maseni odnos jedinjenja Formule l izračunat kao rastvarač-slobodna baza prema polivinilpirolidonu između 1:0,5 i 1:20.
9.Kompozicija prema zahtevu 6, naznačena time , što se upotrebljava hidroksipropil celuloza kao sredstvo matrice.
10.Kompozicija prema zahtevu 9, naznačena time , što je maseni odnos jedinjenja Formule l izračunat kao rastvarač-slobodna baza prema hidroksipropil celulozi između 1:0,5 i 1:20.
11.Kompozicija prema bilo kom od prethodnih zahteva, naznačena time , što se čvrsta disperzija sastoji od kroskarmeloza natrijuma, natrijum skrob glikolata, krospovidona, nisko supstituisane hidroksipropil celuloze, skroba, mikrokristalne celuloze ili njihovih kombinacija.
12.Kompozicija prema zahtevu 8, naznačena time , što čvrsta disperzija sadrži polivinilpirolidon i kroskarmeloza natrijum.
13.Kompozicija prema zahtevu 8, naznačena time , što čvrsta disper zija sadrži polivinilpirolidon i natrijum skrob glikolat.
14.Kompozicija prema zahtevu 8, naz načena time , što čvrsta disperzija sadrži polivinilpirolidon, kroskarmeloza natrijum i mikrokristalnu celulozu.
15.Kompozicija prema zahtevu 1 O, naznačena time , što čvrsta disperzija sadrži hidroksipropil celulozu i kroskarmeloza natrijum.
16.Kompozicija prema zahtevu 1O, naznačena time, što čvrsta dispeizija sadrži hidroksipropil celulozu i bar jedno vezivno sredstvo koje je šećer, šećerni alkohol, ciklodekstrin.
17.Kompozicija prema bilo kom od prethodnih zahteva, na značena time, što je čvrsta disperzija suštinski homogena.
18.Kompozicija prema bilo kom od prethodnih zahteva, na značena time , što sadrži jedinjenje Formule l u suštinski amorfnom obliku.
19.Kompozicija kako je zatražena zaštita prema bilo kom od prethodnih zahteva, naznačena time , što predstavlja farmaceutsku kompoziciju za oralnu davanje.
20.Kompozicija kako je zatražena zaštita prema bilo kom od prethodnih zahteva, naznačena time , što predstavlja farmaceutsku kompoziciju u obliku tablete.
21.Kompozicija kako je zatražena zaštita prema bilo kom od prethodnih zahteva, naznačena time , što predstavlja farmaceutsku kompoziciju u obliku kapsule.
22.Kompozicija kako je zatražena zaštita prema bilo kom od prethodnih zahteva, naznačena time , što predstavlja farmaceutsku kompoziciju u obliku pudera, granulata ili kesice.
23.Postupak za pripremanje čvrste disperzije jedinjenja Formule l ,naznačen time, što se sastoji od simultanog izlaganja jedinjenja Formule l i bar jednog sredstva matrice istiskivanju vrele otopine, oblaganju vrelom otopinom, očvršćivanja rasprskavanjem, zamrzavanjem, tehnikama isparavanja rastvarača ili njihovim kombinacijama.
24.Postupak prema zahtevu 23, naznačen time , što se čvrsta disperzija priprema izlaganjem jedinjenja Formule l i bar jednog sredstva matrice istiskivanju vrele otopine.
25.Postupak prema zahtevu 23, naznačen time , što se čvrsta disperzija priprema izlaganjem jedinjenja Formule l i bar jednog sredstva matrice tehnikama isparavanja rastvarača.
26.Postupak prema zahtevu 25, naznačen time , što se rastvarač sastoji od jednog ili više rastvarač odabranih od grupe koja sadrži metanol, etanol, n-propanol, izopropanol i aceton.
27.Postupak prema zahtevu 26, naznačen time , što se kao rastvarač upotrebljava smeša etanola i acetona.
28.Postupak kako je zatražena zaštita u zahtevima 23 do 27, naznačen time, što se čvrsta disperzija dalje tretira bar sa još jednim korakom u postupku, kao što je mlevenje, prosejavanje, valjanje radi postizanja kompaktnosti, drobljenje, sejanje, smešanje ili njihova kombinacija.
29.Postupak kako je zatražena zaštita u zahtevima 23 do 28, naznačen time , što se sastoji od dodatnog koraka stvaranja jedinjenja čvrste disperzije sa jednim ili više farmaceutski prihvatljivih vezivnih sredstava da se formira smeša i oblikovanja ove smeše u tablete, punjene kapsule i kesice.
30.Farmaceutska kompozicija, naznačena time , što se uvek proizvodi postupkom bilo kog od zahteva 23 do 29.
31.Postupak za lečenje hiper-proliferativnih poremećaja, naznačen time , što se sastoji od davanja farmaceutske kompozicije prema bilo kom od zahteva 1 do 22 i 30 sisaru, uključujući čoveka, bilo kao jedino sredstvo ili u kombinaciji sa drugim terapijama.
32.Postupak za lečenje kancera, naznačen time, što se sastoji od davanja farmaceutske kompozicije prema bilo kom od zahteva 1 do 22 i 30 sisaru, uključujući čoveka, bilo kao jedino sredstvo ili u kombinaciji sa drugim terapijama.
33.Postupak za lečenje kancera, naznačen time, što se sastoji od davanja farmaceutske kompozicije prema bilo kom od zahteva 1 do 22 i 30 sisaru, uključujući čoveka, bilo kao jedino sredstvo ili u kombinaciji sa radioaktivnom terapijom.
34.Postupak za lečenje kancera, naznačen time, što se sastoji od davanja farmaceutske kompozicije prema bilo kom od zahteva 1 do 22 i 30 sisaru, uključujući čoveka, u kombinaciji sa citotoksičnom terapijom.
35.Postupak za lečenje kancera, naznačen time , što se sastoji od davanja farmaceutske kompozicije prema bilo kom od zahteva 1 do 22 i 30 sisaru, uključujući čoveka, u kombinaciji sa nekom drugom anti-kancer terapijom koja cilja bilo VEGFR, PDGFR, src, abi flt-3, EGFR, HER-2, aurora, raf, MEK, ERK, Pl-3 kinazu, AKT, mTOR, ili HDAC.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60475204P | 2004-08-27 | 2004-08-27 | |
| PCT/US2005/030541 WO2006026500A1 (en) | 2004-08-27 | 2005-08-29 | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME00152B true ME00152B (me) | 2010-10-10 |
Family
ID=35517032
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-358A ME00152B (me) | 2004-08-27 | 2005-08-29 | Nove farmaceutske kompozicije 4-(4-(3-(4-hlor0 -3-trifluorometil-fenil)-ureid0)-3-fluoro-fenoksi)piridin-2-karbonska kiseline za lečenje hiper-prolifera tivnih poremećaja |
| MEP-358/08A MEP35808A (en) | 2004-08-27 | 2005-08-29 | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-358/08A MEP35808A (en) | 2004-08-27 | 2005-08-29 | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US20060058358A1 (me) |
| EP (2) | EP2589384A1 (me) |
| JP (1) | JP5017115B2 (me) |
| KR (1) | KR101336737B1 (me) |
| CN (2) | CN102885813A (me) |
| AR (1) | AR050616A1 (me) |
| AU (1) | AU2005279996A1 (me) |
| BR (1) | BRPI0514715B1 (me) |
| CA (1) | CA2578438C (me) |
| CL (1) | CL2010001484A1 (me) |
| CR (1) | CR8980A (me) |
| CY (1) | CY2017038I2 (me) |
| DK (1) | DK1793824T3 (me) |
| EA (1) | EA010832B1 (me) |
| EC (1) | ECSP077299A (me) |
| ES (1) | ES2561618T3 (me) |
| GT (1) | GT200500230A (me) |
| HN (1) | HN2005000484A (me) |
| HR (1) | HRP20160156T1 (me) |
| HU (2) | HUE026654T2 (me) |
| IL (1) | IL181590A (me) |
| LT (1) | LTC1793824I2 (me) |
| LU (1) | LUC00047I2 (me) |
| MA (1) | MA28911B1 (me) |
| ME (2) | ME00152B (me) |
| MX (1) | MX2007002397A (me) |
| MY (1) | MY191349A (me) |
| NI (1) | NI200700064A (me) |
| NO (2) | NO343937B1 (me) |
| NZ (1) | NZ553557A (me) |
| PE (2) | PE20100432A1 (me) |
| PL (1) | PL1793824T3 (me) |
| PT (1) | PT1793824E (me) |
| RS (1) | RS54580B1 (me) |
| SI (1) | SI1793824T1 (me) |
| TN (1) | TNSN07076A1 (me) |
| TW (1) | TWI369987B (me) |
| UA (1) | UA92472C2 (me) |
| UY (1) | UY29086A1 (me) |
| WO (1) | WO2006026500A1 (me) |
| ZA (1) | ZA200702392B (me) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| CA2359244C (en) * | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
| EP2324825A1 (en) * | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
| UY28213A1 (es) * | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| DE602004007382T2 (de) * | 2003-05-20 | 2008-04-17 | Bayer Pharmaceuticals Corp., West Haven | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
| DK1663978T3 (da) * | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
| WO2006034797A1 (en) * | 2004-09-29 | 2006-04-06 | Bayer Healthcare Ag | Thermodynamically stable form of bay 43-9006 tosylate |
| KR101335932B1 (ko) * | 2005-03-07 | 2013-12-04 | 바이엘 헬스케어 엘엘씨 | 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물 |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US20090074917A2 (en) * | 2006-07-26 | 2009-03-19 | Remington Direct Lp | Low-calorie, no laxation bulking system |
| US20080026038A1 (en) * | 2006-07-26 | 2008-01-31 | Remington Direct Lp | No laxation, low flatulence bulking system |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| MX2009004861A (es) * | 2006-11-09 | 2009-05-21 | Abbott Gmbh & Co Kg | Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa. |
| EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
| AR065720A1 (es) * | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| WO2008138755A2 (en) * | 2007-05-11 | 2008-11-20 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for poorly soluble drugs |
| WO2009114703A2 (en) * | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
| UA107186C2 (xx) * | 2008-12-03 | 2014-12-10 | Тверді форми дозування бендамустину | |
| US9101631B2 (en) | 2008-12-12 | 2015-08-11 | Georgetown University | Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer |
| JO3112B1 (ar) * | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
| AR081060A1 (es) * | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| KR20130109092A (ko) * | 2010-06-09 | 2013-10-07 | 아보트 러보러터리즈 | 키나제 억제제를 함유하는 고체 분산물 |
| HUE049986T2 (hu) | 2010-07-12 | 2020-11-30 | Salix Pharmaceuticals Inc | Rifaximin készítmények és ezek alkalmazásai |
| EP2595628A1 (en) | 2010-07-19 | 2013-05-29 | Bayer HealthCare LLC | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| EP2621486A1 (en) | 2010-10-01 | 2013-08-07 | Bayer Intellectual Property GmbH | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
| SG10201801794WA (en) | 2010-10-29 | 2018-04-27 | Abbvie Inc | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CN103301066B (zh) * | 2012-03-15 | 2018-12-07 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
| UY35006A (es) * | 2012-09-06 | 2014-03-31 | Bayer Healthcare Llc | Composición farmacéutica recubierta que contiene regorafenib |
| US9211290B2 (en) * | 2012-12-31 | 2015-12-15 | Noven Therapeutics, Llc | Solid dispersions of amorphous paroxetine mesylate |
| WO2015049698A2 (en) * | 2013-10-04 | 2015-04-09 | Hetero Research Foundation | Process for regorafenib |
| CN104721142B (zh) * | 2013-12-18 | 2020-04-28 | 山东新时代药业有限公司 | 一种利伐沙班固体分散体及其制备方法 |
| WO2016005874A1 (en) * | 2014-07-09 | 2016-01-14 | Shilpa Medicare Limited | Process for the preparation of regorafenib and its crystalline forms |
| CN105267167A (zh) * | 2015-09-11 | 2016-01-27 | 江苏嘉逸医药有限公司 | 一种瑞戈非尼口服固体药物组合物的制备方法 |
| CN105330600B (zh) * | 2015-11-30 | 2018-05-22 | 山东罗欣药业集团股份有限公司 | 一种瑞戈菲尼的制备方法 |
| CN105879049B (zh) * | 2016-05-13 | 2019-03-26 | 浙江大学 | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 |
| CN107661296A (zh) * | 2016-07-27 | 2018-02-06 | 江苏先声药业有限公司 | 一种瑞戈非尼固体分散体及其制备方法 |
| PL3518924T3 (pl) | 2016-09-30 | 2023-01-09 | Salix Pharmaceuticals, Inc. | Postacie stałej dyspersji ryfaksyminy |
| CN111166724A (zh) * | 2018-11-09 | 2020-05-19 | 北京化工大学 | 一种瑞戈非尼纳米分散体、片剂及其制备方法 |
| EP3861989A1 (en) | 2020-02-07 | 2021-08-11 | Bayer Aktiengesellschaft | Pharmaceutical composition containing regorafenib and a stabilizing agent |
| US20230119355A1 (en) * | 2020-03-05 | 2023-04-20 | Aurigene Discovery Technologies Limited | Pharmaceutical compositions of a kinase inhibitor |
| CN116018133A (zh) | 2020-06-26 | 2023-04-25 | 博士医疗爱尔兰有限公司 | 靶向释放利福昔明组合物 |
| CN112587485A (zh) * | 2021-01-08 | 2021-04-02 | 湖南南新制药股份有限公司 | 一种药物固体分散体及其制备方法 |
| CN112842998A (zh) * | 2021-01-19 | 2021-05-28 | 深圳市简一生物科技有限公司 | 一种瑞戈非尼分散剂及其制备方法 |
| FR3123358B1 (fr) * | 2021-05-25 | 2024-05-10 | Vecormat Bfc | Procédé d’élaboration d’un matériau naturel composite à faible emprunte carbone et fort taux de matière naturelle. |
| WO2022253945A1 (en) | 2021-06-04 | 2022-12-08 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide |
| CN114767633B (zh) * | 2022-04-07 | 2023-03-31 | 郑州大学第一附属医院 | 含抗乳腺癌药物他莫昔芬的固体分散体、制备方法及制剂 |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
| US4220302A (en) | 1978-07-21 | 1980-09-02 | Hampton Diane M | Nursing bottle holder |
| AU1537292A (en) * | 1991-04-16 | 1992-11-17 | Nippon Shinyaku Co. Ltd. | Method of manufacturing solid dispersion |
| EP1049664B1 (en) * | 1997-12-22 | 2005-03-16 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas |
| SK285371B6 (sk) * | 1997-12-22 | 2006-12-07 | Bayer Corporation | Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom |
| HUP0101704A3 (en) * | 1997-12-22 | 2002-12-28 | Bayer Corp Pittsburgh | Kinease substituted heterocyclic ureas with raf inhibition activity and pharmaceutical compositions containing them |
| CA2359244C (en) * | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| PT1690853E (pt) * | 1999-01-13 | 2010-04-23 | Bayer Healthcare Llc | Difenilureias substituídas com w-carboxiarilo como inibidores de raf-quinase |
| JP3789066B2 (ja) | 1999-12-08 | 2006-06-21 | 三菱電機株式会社 | 液晶表示装置 |
| HUP0300429A2 (hu) * | 2000-04-19 | 2003-07-28 | Fujisawa Pharmaceutical Co., Ltd. | Javított felszívódási képességű szilárd diszperzió és eljárás az előállítására |
| US8725620B2 (en) | 2000-07-10 | 2014-05-13 | Nobuyoshi Morimoto | System and method for negotiating improved terms for products and services being purchased through the internet |
| EP1308156A4 (en) * | 2000-08-11 | 2009-07-15 | Eisai R&D Man Co Ltd | AGGREGATE SOLID DISPERSION WITH IMPROVED SOLUBILITY |
| CN1487935A (zh) | 2000-12-11 | 2004-04-07 | ����ҩƷ��ҵ��ʽ���� | 改良型水溶性药物组合物 |
| US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| CN1491104A (zh) * | 2001-02-13 | 2004-04-21 | 新型改进释放制剂 | |
| SE0103838D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
| AU2002365899B2 (en) * | 2001-12-04 | 2007-09-13 | Onyx Pharmaceuticals, Inc. | RAF-MEK-ERK pathway inhibitors to treat cancer |
| US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| CN1688291A (zh) * | 2002-02-01 | 2005-10-26 | 辉瑞产品公司 | 含有固体药物分散体的即刻释放剂型 |
| EP2324825A1 (en) * | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
| CA2430180C (en) | 2003-05-21 | 2010-03-16 | Royal Group Technologies Limited | Cascade shade |
| DK1663978T3 (da) * | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
| CN101048140B (zh) * | 2004-08-27 | 2013-06-19 | 拜尔保健公司 | 用于治疗癌症的药物组合物 |
-
2005
- 2005-08-25 MY MYPI20054000A patent/MY191349A/en unknown
- 2005-08-26 US US11/212,109 patent/US20060058358A1/en not_active Abandoned
- 2005-08-26 AR ARP050103568A patent/AR050616A1/es not_active Application Discontinuation
- 2005-08-26 HN HN2005000484A patent/HN2005000484A/es unknown
- 2005-08-26 UY UY29086A patent/UY29086A1/es not_active Application Discontinuation
- 2005-08-26 PE PE2010000029A patent/PE20100432A1/es active IP Right Grant
- 2005-08-26 TW TW094129395A patent/TWI369987B/zh not_active IP Right Cessation
- 2005-08-26 PE PE2005000984A patent/PE20060505A1/es active IP Right Grant
- 2005-08-26 GT GT200500230A patent/GT200500230A/es unknown
- 2005-08-29 EP EP13151040.6A patent/EP2589384A1/en not_active Withdrawn
- 2005-08-29 ME MEP-2008-358A patent/ME00152B/me unknown
- 2005-08-29 DK DK05792486.2T patent/DK1793824T3/en active
- 2005-08-29 PL PL05792486T patent/PL1793824T3/pl unknown
- 2005-08-29 NZ NZ553557A patent/NZ553557A/en not_active IP Right Cessation
- 2005-08-29 EA EA200700501A patent/EA010832B1/ru unknown
- 2005-08-29 CN CN2012102807209A patent/CN102885813A/zh active Pending
- 2005-08-29 UA UAA200703203A patent/UA92472C2/ru unknown
- 2005-08-29 PT PT57924862T patent/PT1793824E/pt unknown
- 2005-08-29 BR BRPI0514715-8A patent/BRPI0514715B1/pt active IP Right Grant
- 2005-08-29 ES ES05792486.2T patent/ES2561618T3/es not_active Expired - Lifetime
- 2005-08-29 EP EP05792486.2A patent/EP1793824B1/en not_active Revoked
- 2005-08-29 ME MEP-358/08A patent/MEP35808A/xx unknown
- 2005-08-29 KR KR1020077006801A patent/KR101336737B1/ko not_active Expired - Lifetime
- 2005-08-29 RS RS20160039A patent/RS54580B1/sr unknown
- 2005-08-29 CA CA2578438A patent/CA2578438C/en not_active Expired - Lifetime
- 2005-08-29 HR HRP20160156TT patent/HRP20160156T1/hr unknown
- 2005-08-29 HU HUE05792486A patent/HUE026654T2/en unknown
- 2005-08-29 AU AU2005279996A patent/AU2005279996A1/en not_active Abandoned
- 2005-08-29 MX MX2007002397A patent/MX2007002397A/es active IP Right Grant
- 2005-08-29 CN CNA2005800371513A patent/CN101287463A/zh active Pending
- 2005-08-29 JP JP2007533489A patent/JP5017115B2/ja not_active Expired - Lifetime
- 2005-08-29 WO PCT/US2005/030541 patent/WO2006026500A1/en not_active Ceased
- 2005-08-29 SI SI200532037T patent/SI1793824T1/sl unknown
-
2007
- 2007-02-26 TN TNP2007000076A patent/TNSN07076A1/en unknown
- 2007-02-27 IL IL181590A patent/IL181590A/en active IP Right Grant
- 2007-02-27 NI NI200700064A patent/NI200700064A/es unknown
- 2007-03-05 EC EC2007007299A patent/ECSP077299A/es unknown
- 2007-03-07 CR CR8980A patent/CR8980A/es unknown
- 2007-03-22 ZA ZA200702392A patent/ZA200702392B/xx unknown
- 2007-03-22 MA MA29767A patent/MA28911B1/fr unknown
- 2007-03-26 NO NO20071584A patent/NO343937B1/no active Protection Beyond IP Right Term
-
2010
- 2010-12-20 CL CL2010001484A patent/CL2010001484A1/es unknown
-
2016
- 2016-03-22 LT LTPA2016008C patent/LTC1793824I2/lt unknown
-
2017
- 2017-01-27 US US15/417,469 patent/US20170165243A1/en not_active Abandoned
- 2017-11-08 LU LU00047C patent/LUC00047I2/fr unknown
- 2017-11-09 CY CY2017038C patent/CY2017038I2/el unknown
- 2017-11-21 HU HUS1700047C patent/HUS1700047I1/hu unknown
-
2019
- 2019-08-05 NO NO2019033C patent/NO2019033I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ553557A (en) | New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders | |
| CA2681465C (en) | Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom | |
| WO1999033467A1 (en) | Method and composition of an oral preparation of itraconazole | |
| JP2004504360A (ja) | １−（５−ｔｅｒｔ−ブチル−２−Ｐ−トリル−２Ｈ−ピラゾール−３−イル）−３−［４−（２−モルホリン−４−イル−エトキシ）−ナフタレン−１−イル］−ウレアの改良された経口製剤 | |
| EP2595607A2 (de) | Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer | |
| EP3648745B1 (en) | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition | |
| EP2585050B1 (de) | Silodosin-cyclodextrin einschlussverbindungen | |
| CN104940160A (zh) | 改进的磷酸奥司他韦固体组合物及其制备方法 | |
| CN103845332B (zh) | 一种达沙替尼药用组合物及其制备方法 | |
| CN103800334B (zh) | 甲磺酸伊马替尼的药物组合物及其制备方法 | |
| EP4424303A1 (en) | Lenvatinib composition with improved bioavailability | |
| CN107865826B (zh) | 一种e构型苯甲酰胺类化合物的固体分散体 | |
| CN106389428B (zh) | 一种具有提高阿齐沙坦生物利用度和稳定性的组合物及制备方法 | |
| CN105560200B (zh) | 难溶性药物控释片及其制备方法 | |
| JP6250911B2 (ja) | ５−（４−（アミノスルホニル）フェニル）−２，２−ジメチル−４−（３−フルオロフェニル）−３（２ｈ）−フラノンを含む薬学的組成物、及び薬学的組成物を含むカプセル製剤 | |
| CN109125320A (zh) | 一种吡啶类化合物的药物组合物 | |
| JP7300725B2 (ja) | 固形製剤及びその製造方法 | |
| JP6669937B2 (ja) | ５−ｈｔ６拮抗薬の医薬組成物 | |
| CN106860407A (zh) | 一种利伐沙班片 | |
| TH103179A (th) | สารผสมทางยาชนิดใหม่สำหรับการบำบัดความผิดปกติของการเพิ่มจำนวนมากเกิน | |
| TH39245B (th) | สารผสมทางยาชนิดใหม่สำหรับการบำบัดความผิดปกติของการเพิ่มจำนวนมากเกิน | |
| Pimple et al. | Formulation and evaluation of immediate release tablets of s (-) metoprolol succinate using roller compaction approach | |
| RU2195292C1 (ru) | Фармацевтическая композиция, обладающая противоязвенным и антацидным действием | |
| CN104758938B (zh) | 一种治疗高血压的非洛地平片剂及其制备方法 | |
| WO2005049024A2 (de) | Feste pharmazeutische zubereitungsform |